View Older Stories

Jun 8, 2026 04:05PM Neurocrine presents tardive dyskinesia treatment data at conference

Jun 8, 2026 08:31AM Neurocrine presents INGREZZA data for tardive dyskinesia patients

Jun 5, 2026 08:59AM Morgan Stanley tracks prescription trends for US neurology drugs

Jun 3, 2026 08:31AM Neurocrine to present two-year CRENESSITY data at medical meeting

Jun 2, 2026 05:07AM Goldman Sachs Resumes Neurocrine Bio. (NBIX) at Buy

May 21, 2026 04:37PM Bernstein SocGen Group Starts Neurocrine Bio. (NBIX) at Outperform

May 18, 2026 04:06PM Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia

May 6, 2026 01:16PM Neurocrine Bio. (NBIX) PT Raised to $155 at Truist Securities

May 6, 2026 08:32AM Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY

May 6, 2026 06:33AM Neurocrine Bio. (NBIX) PT Raised to $176 at Wedbush

May 6, 2026 06:12AM Neurocrine Bio. (NBIX) PT Raised to $230 at Oppenheimer

May 5, 2026 04:14PM Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue

May 1, 2026 04:06PM Neurocrine shows sustained pediatric results for CRENESSITY in two-year study

Apr 29, 2026 04:07PM Neurocrine publishes tardive dyskinesia scale validation research

Apr 22, 2026 04:05PM Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients

Apr 14, 2026 08:32AM INGREZZA shows higher treatment persistence than AUSTEDO XR in study

Apr 10, 2026 06:06AM Neurocrine Bio. (NBIX) PT Raised to $185 at Morgan Stanley

Apr 8, 2026 07:13AM Neurocrine Bio. (NBIX) PT Raised to $215 at H.C. Wainwright

Apr 7, 2026 05:01AM Neurocrine Bio. (NBIX) PT Raised to $242 at Citi

Apr 6, 2026 03:49PM Neurocrine Bio. (NBIX) PT Raised to $166 at Wedbush

Apr 6, 2026 02:41PM Neurocrine Bio. (NBIX) PT Raised to $200 at Canaccord

Apr 6, 2026 01:59PM Neurocrine Bio. (NBIX) PT Raised to $220 at Oppenheimer on SLNO deal

Apr 6, 2026 01:10PM Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition

Apr 6, 2026 09:35AM UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX) Following Reports of Soleno Acquisition

Apr 6, 2026 05:53AM Neurocrine Biosciences nearing over $2.5B deal for Soleno Therapeutics

Mar 26, 2026 08:33AM Neurocrine presents tardive dyskinesia treatment guidance for elderly

Mar 17, 2026 04:09PM Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer

Mar 10, 2026 09:22AM Neurocrine Bio. (NBIX) PT Raised to $195 at Cantor Fitzgerald on Ingrezza Outlook

Feb 24, 2026 09:07AM Wolfe Research Starts Neurocrine Bio. (NBIX) at Outperform

Feb 24, 2026 08:53AM RBC Capital: 'We see upside in multiple scenarios, and so would remain buyers'

Feb 17, 2026 09:45AM Neurocrine Bio. (NBIX) PT Lowered to $140 at Truist Securities

Feb 17, 2026 09:27AM Neurocrine Bio. (NBIX) PT Lowered to $140 at BMO Capital

Feb 12, 2026 07:26AM Canaccord Genuity Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Feb 12, 2026 07:11AM Neurocrine Bio. (NBIX) PT Lowered to $192 at H.C. Wainwright

Feb 11, 2026 04:04PM Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c ; Offers Guidance

Jan 30, 2026 10:08AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX), Optimistic on Ingrezza

Jan 15, 2026 08:32AM Neurocrine presents data showing INGREZZA achieved higher target occupancy

Jan 12, 2026 06:26AM Data center investments to hit $3 trillion over next five years, says Moody’s

Jan 8, 2026 08:49AM 4Q25/2026 Biotech Earnings Preview: RBC

Jan 8, 2026 03:39AM Morgan Stanley Downgrades Neurocrine Bio. (NBIX) to Equalweight

Jan 5, 2026 09:15AM Neurocrine Bio. (NBIX) PT Lowered to $188 at UBS

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Dec 18, 2025 06:46AM Neurocrine Bio. (NBIX) PT Raised to $198 at H.C. Wainwright

Dec 17, 2025 08:19AM TD Cowen on Neurocrine Bio. (NBIX): 'R&D Day Highlights Uniquely Diversified And Robust Early Pipeline'

Dec 17, 2025 04:27AM Jefferies Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Dec 17, 2025 04:12AM BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX)

Dec 17, 2025 04:12AM RBC Capital Reiterates Outperform Rating on Neurocrine Bio. (NBIX)

Dec 12, 2025 03:37AM Neurocrine Bio. (NBIX) PT Raised to $175 at Mizuho

Dec 10, 2025 09:16AM TD Cowen: 'Neurocrine Bio. (NBIX) Is a Top Biotech Pick'

Dec 8, 2025 05:18AM Neurocrine Bio. (NBIX) PT Raised to $180 at RBC Capital

View Older Stories